Press coverage about Threshold Pharmaceuticals (NASDAQ:MTEM) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Threshold Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.4048948458727 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Several research firms have recently commented on MTEM. ValuEngine raised shares of Threshold Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Ladenburg Thalmann Financial Services began coverage on shares of Threshold Pharmaceuticals in a research note on Thursday, August 3rd. They issued a “buy” rating and a $10.00 price objective for the company. Stifel Nicolaus reissued a “hold” rating and issued a $0.40 price objective on shares of Threshold Pharmaceuticals in a research note on Thursday, August 3rd. Finally, Zacks Investment Research lowered shares of Threshold Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th.

Threshold Pharmaceuticals (MTEM) opened at $7.99 on Tuesday. Threshold Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $11.88.

ILLEGAL ACTIVITY WARNING: “Threshold Pharmaceuticals (MTEM) Earning Somewhat Favorable Media Coverage, Accern Reports” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at

Threshold Pharmaceuticals Company Profile

Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

Insider Buying and Selling by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)

Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.